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Abstract
Background: Risk of exacerbations in chronic obstructive pulmonary disease (COPD) associated with biomass
smoke has not been well addressed, although biomass smoke is similar in composition to tobacco smoke.
Methods: To investigate whether the risk of exacerbations in COPD associated with biomass smoke differs from
that in COPD associated with tobacco smoke, we recruited patients with COPD from two Korean multicenter
prospective cohorts. In a multiple linear regression model, the standardized regression coefficient (β) of biomass
smoke exposure ≥25 years was most similar to that (β′) of tobacco smoke exposure ≥10 pack-years (β = − 0.13 and
β′ = − 0.14). We grouped patients with COPD into four categories based on the above cut-offs: Less Tobacco-Less
Biomass, Less Tobacco-More Biomass, More Tobacco-Less Biomass, and More Tobacco-More Biomass. The main
outcome was the incidence of moderate or severe exacerbations.
Results: Among 1033 patients with COPD, 107 were included in Less Tobacco-Less Biomass (mean age: 67 years,
men: 67%), 40 in Less Tobacco-More Biomass (mean age: 70 years, men: 35%), 631 in More Tobacco-Less Biomass
(mean age: 68 years, men: 98%), and 255 in More Tobacco-More Biomass (mean age: 69 years, men: 97%). The
incidence rates of exacerbations were not significantly different between Less Tobacco-More Biomass and More
Tobacco-Less Biomass (adjusted incidence rate ratio, 1.03; 95% confidence interval, 0.56–1.89; P = 0.921). No
interaction between sex and tobacco and biomass smoke was observed. When propensity score matching with
available covariates including age and sex was applied, a similar result was observed.
Conclusions: Patients with COPD associated with biomass smoke and those with COPD associated with tobacco
smoke had a similar risk of exacerbations. This suggests that patients with COPD associated with biomass smoke
should be treated actively.
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Background
Biomass smoke exposure is an important risk factor for
the development of chronic obstructive pulmonary dis-
ease (COPD), even though tobacco smoking is the most
well-studied COPD risk factor [1–6]. The World Health
Organization reported that more than 40% of the world’s
population continues to depend on biomass fuels for
cooking and heating, and indoor air pollution caused by
these activities was responsible for 7.7% of the global
mortality in 2012 [7]. Approximately 25% of premature
deaths from COPD in low- and middle-income countries
are due to exposure to biomass smoke exposure [8].
The clinical characteristics of COPD associated with
biomass smoke are different from those associated with
tobacco smoke. Patients with COPD associated with bio-
mass smoke are predominantly women, and have worse
symptoms and quality of life than do those with COPD
associated with tobacco smoke [9, 10]. Recent studies
have found phenotypic differences between COPD asso-
ciated with either biomass or tobacco smoke exposure
[10–12]. Biomass smoke exposure is associated with a
small airway disease phenotype, whereas tobacco smoke
exposure is associated with an emphysema phenotype.
However, only a few longitudinal studies have com-
pared the outcomes between COPD associated with bio-
mass smoke and tobacco smoke [13, 14], and no studies
have investigated the risk of exacerbations in patients
with COPD exposed to biomass smoke in a prospective
study. Exacerbations of COPD are important outcomes
in the management of COPD since they negatively im-
pact the health status, hospital admissions and readmis-
sions, disease progression, and mortality [1, 15]. Thus,
we aimed to determine whether the risk of exacerbations
in COPD associated with biomass smoke differs from
that in COPD associated with tobacco smoke. We hy-
pothesized that patients with COPD associated with bio-
mass smoke would have a lower risk of exacerbations
than those with COPD associated with tobacco smoke
as the rate of FEV1 decline is slower in patients whose
COPD was associated with biomass smoke than in those
whose COPD was associated with tobacco smoke [14].
Methods
Patients
We recruited participants from two multicenter pro-
spective cohorts in the Republic of Korea: the Korean
Obstructive Lung Disease (KOLD) cohort, which com-
prises participants from 17 centers recruited since 2005
[16], and the Korean COPD Subgroup Study (KOCOSS;
NCT02800499) cohort, which comprises participants
from 45 centers recruited since 2011 [17]. Major exclusion
criteria of the two cohort studies are patients with respira-
tory diseases other than obstructive lung disease (e.g., pre-
vious pulmonary resection, tuberculosis-destroyed lung,
and bronchiectasis). All participants in the cohorts pro-
vided written informed consent. Participants were eligible
for the current study if they were 40 years or older and
had post-bronchodilator forced expiratory volume in 1 s/
forced vital capacity (FEV1/FVC) less than 0.7. Partici-
pants with an unknown exposure history to tobacco and/
or biomass fuel smoke were excluded. Participants who
were followed up for less than 6months and those who did
not have baseline information were also excluded. The
present study was approved by the institutional review board
of the Seoul National University Hospital (H-1706-079-859)
and was conducted in accordance with the tenets of the Dec-
laration of Helsinki.
Definition of exposure groups
At a baseline visit, biomass fuel exposure was deter-
mined by using the same questions in both cohorts:
“Have you ever burned firewood for cooking or heating
by yourself for over a year in your lifetime? If yes, how
many years have you burned firewood as fuel?” and
“Have you ever used coal briquettes for cooking or heat-
ing by yourself for over a year in your lifetime? If yes,
how many years have you used coal briquettes as fuel?”
We defined the exposure years to biomass fuel smoke in
this study as the sum of exposure years to firewood and
coal briquettes. In the Republic of Korea, coal briquettes
had been used as the major source of fuel for cooking
and heating since the 1950s; however, they had been re-
placed by gas and liquid fuels from the early 1990s, and
biomass fuel use is now negligible [18]. To find equivalents
of exposure to tobacco and biomass smoke, we applied
multiple linear regression in the 1031 cohort participants
(mean age, 69 years; 934 men; 55 non-COPD) who were
not currently exposed to tobacco and biomass smoke.
EðYÞ ¼
(
B0 þ B1X1 þ B2X2 þ B3X3 þ B4X4 þ ε; i f X5 ¼ 0
B00 þ B01X1 þ B02X2 þ B03X3 þ B05X5 þ ε0; i f X4 ¼ 0
In the above equation, Y is post-bronchodilator FEV1/
FVC (%) at a baseline visit; X1 is age (0 if age < 60 years
and 1 if age ≥ 60 years); X2 is sex (0 if male and 1 if fe-
male); X3 is height (cm), X4 is tobacco smoke (0 if < m
pack-years and 1 if ≥ m pack-years, where m is an inte-
ger); X5 is biomass smoke (0 if < n years and 1 if ≥ n
years, where n is an integer); B0, B00 are the intercept
terms; B1, B01 to B4, B
0
5 are regression coefficients; and ε,
ε′ are the random error terms. The standardized regres-
sion coefficient [19] of B4 (β) and that of B05 (β
′) were
most similar when m was 10 and n was 25 (β = − 0.13
and β′ = − 0.14) (Table 1). Therefore, the tobacco group
(More Tobacco) was defined as one with ≥10 pack-years
of tobacco smoke, and the biomass group (More Bio-
mass) was defined as one with ≥25 exposure years to
biomass smoke. We grouped patients with COPD into
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four categories based on the above cut-offs: Less
Tobacco-Less Biomass, Less Tobrefacco-More Biomass,
More Tobacco-Less Biomass, and More Tobacco-More
Biomass.
Measurement of variables and outcomes
All participants underwent detailed interviews by study
physicians or trained nurses covering an exposure his-
tory to tobacco and biomass smoke; a history of exacer-
bations during the previous year; and symptom scores,
including those for the modified Medical Research
Council (mMRC) Questionnaire [20], St. George’s re-
spiratory questionnaire for COPD (SGRQ-C) [21], and
COPD assessment test (CAT) [22]. Participants underwent
pre- and post-bronchodilator spirometry at baseline. After
a baseline visit, participants were followed up every 3
months (the KOLD cohort) or 6months (the KOCOSS co-
hort). The use of drugs, including long-acting muscarinic
antagonists, long-acting β-agonists, and inhaled corticoste-
roids at enrollment and the medication possession ratios of
those drugs during the follow-up period were recorded.
The main outcome was the incidence of moderate or
severe exacerbations. An exacerbation was defined as
moderate when any worsening of respiratory symptoms
led to treatment with systemic corticosteroids, antibi-
otics, or both, and severe if it led to hospital admission
or emergency department visits [15, 23].
Statistical analysis
Clinical characteristics were compared using independ-
ent samples t-tests or one-way analysis of variance for
continuous variables. For categorical variables, compari-
sons were made using either χ2 tests or Fisher’s exact
tests. The incidence rates of moderate or severe exacer-
bations were compared in the four exposure groups by
using negative binomial regression models. The time to
the first moderate or severe exacerbation was analyzed
using the Kaplan–Meier method. Thereafter, we re-
peated the analyses after propensity score matching.
Multivariable logistic regression was used to compute the
propensity score for the Less Tobacco-More Biomass group
by using available covariates. The Less Tobacco-More Bio-
mass group was matched (1:3 ratio) with the More
Tobacco-Less Biomass group by using the nearest neighbor
method within a caliper of 0.3 of the propensity score. We
also performed sensitivity analysis with four groups of pa-
tients (never exposed to tobacco or biomass smoke, ex-
posed to biomass smoke only, exposed to tobacco smoke
only, and exposed to both biomass and tobacco smoke). P
values less than 0.05 were considered significant. Statistical
analyses were performed using Stata statistical software
(Version 14.2; StataCorp, College Station, TX).
Results
Among the 1033 patients with COPD who were followed up
for a mean duration of 3.0 years, 107 (10.4%) were included
in the Less Tobacco-Less Biomass group, 40 (3.9%) in the
Less Tobacco-More Biomass group, 631 (61.1%) in the More
Tobacco-Less Biomass group, and 255 (24.7%) in the More
Tobacco-More Biomass group (Fig. 1). Characteristics of the
study patients according to exposure are presented in Table 2.
Patients in the Less Tobacco-More Biomass group were
more likely to be women (65.0 vs. 2.2%; P < 0.001) and older
(69.9 ± 6.5 vs. 67.5 ± 7.6 years; P= 0.061) than those in the
More Tobacco-Less Biomass group (see Additional file 1:
Table S1). Although the mMRC dyspnea scores were similar
in the four groups, comprehensive symptom assessment
questionnaires showed that the Less Tobacco-More Biomass
group had significantly more symptoms. Post-bronchodilator
Table 1 The equivalents of pack-years of tobacco smoke and exposure years to biomass smoke*
If biomass smoke < n years If tobacco smoke < m pack-years
Tobacco smoke (m), pack-years Exposure to biomass smoke (n), years B4 SE β P value B05 SE β
′ P value
10 10 −4.22 1.79 −0.12 0.019 −0.15 1.87 −0.01 0.937
15 −3.48 1.48 −0.10 0.019 0.37 1.83 0.02 0.840
20 −3.51 1.44 −0.11 0.015 −0.14 1.83 −0.01 0.941
25 −4.20 1.32 −0.13 0.002 −3.83 1.92 −0.14 0.048
30 −4.12 1.30 −0.13 0.002 −2.24 2.00 −0.08 0.263
20 10 −4.36 1.43 −0.15 0.003 0.51 1.59 0.02 0.749
15 −3.60 1.24 −0.13 0.004 0.74 1.58 0.03 0.639
20 −3.62 1.21 −0.13 0.003 0.38 1.60 0.02 0.811
25 −4.39 1.11 −0.15 < 0.001 −3.25 1.68 −0.12 0.054
30 −4.01 1.09 −0.14 < 0.001 −1.38 1.73 −0.05 0.424
*Multiple linear regression adjusting for age (< 60 vs. ≥60 years), sex, and height (cm). The standardized regression coefficient of B4 (β) and that of B05 (β
′) were
most similar when m was 10 and n was 25 (β = − 0.13 and β′ = − 0.14)
B4 unstandardized regression coefficient for tobacco smoke, B
0
5 unstandardized regression coefficient for biomass smoke, β standardized regression coefficient of
B4, β
′ standardized regression coefficient of B05, SE standard error
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FEV1% predicted was not significantly different across the
groups (Table 2).
When adjusted for age, sex, body mass index, SGRQ-C
total score (< 25 vs. ≥25), exacerbation history during the
previous year (yes vs. no), and post-bronchodilator FEV1%
predicted, the incidence rates of moderate or severe exacer-
bations did not differ by groups (Table 3). The adjusted inci-
dence rates were 0.72 (95% confidence interval [CI], 0.31–
1.13) in the Less Tobacco-More Biomass group and 0.70
(95% CI, 0.60–0.79) in the More Tobacco-Less Biomass
group, resulting in an incidence rate ratio of 1.03 (95% CI,
0.56–1.89; P= 0.921). No interaction between sex and to-
bacco smoke (< 10 vs. ≥10 pack-years) and biomass smoke
(< 25 vs. ≥25 years) was observed (data not shown). In
addition, the time to the first moderate or severe exacerba-
tion was not significantly different between the four groups
(log-rank P= 0.200) (Fig. 2a).
After propensity score matching, each of 16 participants
in the Less Tobacco-More Biomass group was matched
with three controls in the More Tobacco-Less Biomass
group, whereas each of six participants in the Less
Tobacco-More Biomass group was matched with a con-
trol in the More Tobacco-Less Biomass group. The clin-
ical characteristics of these matched groups were
comparable (see Additional file 1: Figure S1 and
Table S1). The incidence rates of exacerbations
were not significantly different between the groups
(incidence rate ratio, 1.18; 95% CI, 0.53–2.59; P =
0.687) (Table 4). A similar result was observed in
the time to the first exacerbation (log-rank P =
0.904) (Fig. 2b).
We performed sensitivity analysis with 22 patients
who were never exposed to tobacco or biomass smoke
and 79 exposed to biomass smoke only and 322 exposed
to tobacco smoke only and 610 exposed to both biomass
and tobacco smoke. We found no difference in the rates
of exacerbations between COPD associated with biomass
smoke and that associated with tobacco smoke (see
Additional file 1: Table S2). We also applied a propensity
score-matched analysis. Forty participants exposed to
biomass smoke only were matched with 40 participants
exposed to tobacco smoke only. The incidence rates of
exacerbations were not significantly different between
the groups (incidence rate ratio, 1.05; 95% CI, 0.55–1.98;
P = 0.890; see Additional file 1: Table S3).
Discussion
The present study investigated whether the risk of exac-
erbations differs by exposure to biomass or tobacco
smoke. We found no difference in the rates of exacerba-
tions between COPD associated with biomass smoke
and that associated with tobacco smoke, even in an ana-
lysis with propensity score matching.
When an individual with significant exposures to risk
factors, such as tobacco smoke, indoor/outdoor air pol-
lution, and occupational dusts and chemicals, presents
appropriate symptoms, a diagnosis of COPD is made on
the basis of spirometry, which confirms the presence of
Fig. 1 Flowchart illustrating patient selection. *Body mass index, % predicted post-bronchodilator forced expiratory volume in 1 s (FEV1), exacerbation
history during the previous year, the modified Medical Research Council dyspnea score, and the St. George’s respiratory questionnaire for COPD score
at baselineCOPD chronic obstructive pulmonary disease, KOCOSS Korean COPD Subgroup Study, KOLD Korean Obstructive Lung Disease.
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Table 2 Baseline characteristics of the study patients*
Less Tobacco-Less
Biomass (n = 107)
Less Tobacco-More
Biomass (n = 40)
More Tobacco-Less
Biomass (n = 631)
More Tobacco-More
Biomass (n = 255)
P value
Age, years 67.1 ± 9.3 69.9 ± 6.5 67.5 ± 7.6 69.2 ± 7.1 0.007
Age 0.004
< 60 years 23 (21.5) 2 (5.0) 99 (15.7) 24 (9.4)
≥ 60 years 84 (78.5) 38 (95.0) 532 (84.3) 231 (90.6)
Sex < 0.001
Male 72 (67.3) 14 (35.0) 617 (97.8) 248 (97.3)
Female 35 (32.7) 26 (65.0) 14 (2.2) 7 (2.8)
BMI, kg/m2 23.7 ± 3.3 23.7 ± 3.3 23.0 ± 3.1 22.5 ± 3.4 0.005
Tobacco smoking < 0.001
Never-smoker 70 (65.4) 31 (77.5) 0 (0.0) 0 (0.0)
Former smoker 32 (29.9) 9 (22.5) 447 (70.8) 165 (64.7)
Current smoker 5 (4.7) 0 (0.0) 184 (29.2) 90 (35.3)
Tobacco smoke, pack-years 1.7 ± 2.9 0.8 ± 2.1 45.8 ± 24.9 47.1 ± 25.4 < 0.001
Biomass smoke, years 8.9 ± 7.9 35.5 ± 8.3 5.9 ± 7.5 37.9 ± 11.2 < 0.001
Exacerbation during the previous year 0.164
No 79 (73.8) 25 (62.5) 485 (76.9) 199 (78.0)
Yes 28 (26.2) 15 (37.5) 146 (23.1) 56 (22.0)
mMRC dyspnea score 1.4 ± 0.9 1.7 ± 0.9 1.5 ± 0.9 1.6 ± 0.9 0.083
mMRC dyspnea score 0.455
< 2 63 (58.9) 19 (47.5) 367 (58.2) 139 (54.5)
≥ 2 44 (41.1) 21 (52.5) 264 (41.8) 116 (45.5)
SGRQ-C total score 32.8 ± 18.3 44.4 ± 21.7 32.1 ± 18.1 36.8 ± 18.3 < 0.001
SGRQ-C total score 0.001
< 25 44 (41.1) 9 (22.5) 269 (42.6) 77 (30.2)
≥ 25 63 (58.9) 31 (77.5) 362 (57.4) 178 (69.8)
CAT score (n = 780) 13.9 ± 7.9 18.7 ± 10.0 14.0 ± 7.8 16.2 ± 8.0 < 0.001
CAT score < 0.001
< 10 30 (28.0) 6 (15.0) 156 (24.7) 30 (11.8)
≥ 10 63 (58.9) 23 (57.5) 339 (53.7) 133 (52.2)
Unknown 14 (13.1) 11 (27.5) 136 (21.6) 92 (36.1)
Post-bronchodilator FEV1, % predicted 59.3 ± 18.6 63.4 ± 24.2 60.3 ± 17.7 60.0 ± 19.4 0.685
Post-bronchodilator FVC, % predicted 80.8 ± 17.1 84.3 ± 20.7 88.6 ± 17.2 85.5 ± 18.9 < 0.001
Post-bronchodilator FEV1/FVC, % 53.4 ± 10.3 53.1 ± 12.5 48.3 ± 11.3 49.2 ± 11.3 < 0.001
Bronchodilator response (FEV1, %) 6.4 ± 11.4 8.0 ± 13.7 8.5 ± 10.9 8.6 ± 9.7 0.270
Blood eosinophil, % (n = 868) 3.6 ± 4.4 2.4 ± 1.7 3.6 ± 3.4 3.7 ± 4.0 0.196
Blood eosinophil < 0.001
≤ 5% 68 (63.6) 35 (87.5) 409 (64.8) 180 (70.6)
> 5% 19 (17.8) 2 (5.0) 101 (16.0) 54 (21.2)
Unknown 20 (18.7) 3 (7.5) 121 (19.2) 21 (8.2)
Use of LAMA at enrollment 57 (53.3) 16 (40.0) 329 (52.1) 113 (44.3) 0.090
Use of LABA at enrollment 54 (50.5) 26 (65.0) 329 (52.1) 144 (56.5) 0.273
Use of ICS at enrollment 38 (35.5) 22 (55.0) 263 (41.7) 114 (44.7) 0.147
*Data are presented as mean ± SD or No. (%)
BMI Body mass index, CAT COPD Assessment Test, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, FVC forced vital
capacity, ICS inhaled corticosteroid, LABA long-acting β-agonist, LAMA long-acting muscarinic antagonist, mMRC modified Medical Research Council,
SGRQ-C St. George’s Respiratory Questionnaire for COPD
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Table 3 Adjusted incidence rates of moderate or severe exacerbations by exposure groups
Adjusted incidence rate* (95% CI) Adjusted incidence rate ratio* (95% CI) P value
More Tobacco-Less Biomass 0.70 (0.60–0.79) 1
Less Tobacco-Less Biomass 0.51 (0.33–0.68) 0.73 (0.50–1.05) 0.092
Less Tobacco-More Biomass 0.72 (0.31–1.13) 1.03 (0.56–1.89) 0.921
More Tobacco-More Biomass 0.67 (0.54–0.80) 0.96 (0.76–1.20) 0.698
*Adjusted for age, sex, body mass index, St. George’s Respiratory Questionnaire for COPD (SGRQ-C) total score (< 25 vs. ≥25), exacerbation history during the
previous year (yes vs. no), and post-bronchodilator forced expiratory volume in 1 s (FEV1)% predicted
CI confidence interval
Fig. 2 Kaplan–Meier curves illustrating the time to the first moderate or severe exacerbation in four exposure groups (a) and in two exposure
groups after propensity score matching (b)
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persistent airflow limitation [1]. Tobacco smoke con-
tinues to be recognized as the most commonly encoun-
tered risk factor for COPD. In most clinical studies
including large trials, a history of tobacco smoke expos-
ure has been accepted as a major inclusion criterion to
define COPD [24–27]. The pathogenesis and patho-
physiology of COPD caused by tobacco smoke have
been well-studied, and in vivo and in vitro models of
cigarette smoke-induced COPD have been widely used
[28]. Biomass smoke exposure is now being identified as
an important risk factor for persistent airflow limitation.
However, translational and clinical research on COPD
associated with biomass smoke has been limited, espe-
cially from the perspective of comparing exposure to
biomass smoke and to tobacco smoke [29]. In a Mexican
cohort, the rate of FEV1 decline was slower and more
homogeneous in patients whose COPD was associated
with biomass smoke than in those whose COPD was as-
sociated with tobacco smoke [14]. In the same cohort,
no differences were found in survival between the two
groups after adjusting for confounders [13]. However,
the risk of exacerbations, another important COPD out-
come, in the patients exposed to biomass smoke has not
been well addressed as a few studies investigated it
retrospectively [13, 30].
To our knowledge, ours is the first prospective study
comparing the risk of exacerbations between COPD as-
sociated with biomass smoke and that associated with
tobacco smoke. We recruited 1033 patients with COPD
and grouped them into four categories based on the
presence of risk factors, biomass and/or tobacco smoke.
Patients with COPD exposed to biomass smoke were
predominantly women and older, and presented more
symptoms even with a similar degree of airflow limita-
tion than did those exposed to tobacco smoke. After
adjusting for confounding factors, the rates of moderate or
severe exacerbations did not differ by exposure groups.
When propensity score matching was applied to compare
participants with either biomass or tobacco smoke, a simi-
lar result was observed. Biomass and tobacco smoke shares
common harmful components [31], and a recent experi-
mental study showed that biomass fuel smoke activated
similar pathogenic processes observed in cigarette smoke
exposure in both human airway epithelial cells and mice
[32]. A considerable amount of evidence, from in vivo and
in vitro studies, shows biomass smoke enhances lung in-
flammation and impairs pulmonary anti-microbial defense,
which could lead to exacerbations [31].
Our finding is consistent with that of previous retro-
spective analyses reporting no differences in exacerbations
between patients with COPD associated with tobacco or
biomass smoke [13, 30]. On combining our finding with
that of the previous cohort study, which demonstrated
similar mortality between patients with COPD exposed to
the two different smokes [13], we found that clinical and
radiological differences between COPD associated with
biomass and tobacco smoke may not lead to significant
differences in clinical outcomes. Therefore, clinicians
should suspect a diagnosis of COPD in any patient with a
history of exposure to biomass fuel smoke who has dys-
pnea, chronic cough, or sputum production, and any pa-
tient with COPD associated with biomass smoke should
be treated actively.
As the cumulative amounts of exposure to biomass
smoke, which are comparable to those of exposure to to-
bacco smoke, are unknown, the group exposed to bio-
mass smoke has been defined using arbitrary cut-off
values of exposure duration in years, especially when an
individual’s exposure intensity to biomass smoke is un-
available [30, 33]. Cumulative exposure to biomass
smoke expressed as hour-years, which is the product of
the number of years cooking with biomass fuels multi-
plied by the average number of hours spent daily in the
kitchen [34], was unavailable in our cohort. Instead, we
used the standardized regression coefficient to determine
equivalents of the exposure duration (years) to biomass
smoke and pack-years of tobacco smoke. The exposure
duration to biomass smoke was defined as the sum of
exposure years to firewood and coal briquettes. We ap-
plied multiple linear regression predicting values of the
Table 4 Incidence rates of moderate or severe exacerbations in the propensity score-matched cohort
Incidence rate (95% CI) Incidence rate ratio (95% CI) P value
Model 1* More Tobacco-Less Biomass 0.58 (0.33–0.83) 1
Less Tobacco-More Biomass 0.68 (0.23–1.13) 1.18 (0.53–2.59) 0.687
Model 2† More Tobacco-Less Biomass 0.58 (0.32–0.83) 1
Less Tobacco-More Biomass 0.69 (0.21–1.17) 1.19 (0.51–2.78) 0.685
Model 3‡ More Tobacco-Less Biomass 0.56 (0.32–0.79) 1
Less Tobacco-More Biomass 0.65 (0.22–1.07) 1.16 (0.52–2.58) 0.721
*Model 1: unadjusted
†Model 2: adjusted for sex
‡Model 3: adjusted for sex, and medication possession ratios of long-acting muscarinic antagonists, long-acting β-agonists, and inhaled corticosteroids during the
follow-up period as continuous variables
CI confidence interval
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dependent variable, post-bronchodilator FEV1/FVC (%)
at a baseline visit, in the 1031 cohort participants includ-
ing non-COPD in a cross-sectional design. Upon re-
peated modeling with variable values, we found that the
standardized regression coefficients for each exposure
were most similar when the exposure duration to bio-
mass smoke was 25 years and a history of tobacco smoke
was 10 pack-years (Table 1). However, there are several
limitations in these estimates. First, we thought that a
multiple linear regression model predicting values of the
dependent variable, not post-bronchodilator FEV1/FVC
(%) but diagnosis of COPD, would be ideal for determin-
ing comparable cut-off values of exposures. While there
were only 5% participants without COPD in the KOLD
and KOCOSS cohorts, other prospective cohorts utiliz-
ing the same questionnaire on a history of exposure to
biomass smoke were not available in Korea. Second, our
regression model using the spirometric value as a
dependent variable is still limited by the small number
of participants without COPD. Third, questions asses-
sing biomass exposure were focused on cooking or heat-
ing. However, it is possible that a responder was not a
cook, but still had been exposed to biomass smoke.
Fourth, the exposure duration to biomass smoke was de-
fined as the simple sum of exposure years to firewood
and coal briquettes without weights although the risk of
development of COPD was greater for wood burners
than for coal users [3]. Fifth, exposure to tobacco and/or
biomass smoke under the cut-off values may cause
COPD. Sixth, exposure data on other risk factors for
COPD, such as indoor/outdoor air pollution and occu-
pational dusts, were lacking in our study.
Sex selection bias is a commonly encountered issue in
COPD research associated with biomass smoke [11].
The present study also has the limitation as patients
with COPD associated with biomass smoke were pre-
dominantly women. To mitigate the bias, we applied a
propensity score-matched analysis with available covari-
ates including sex. This approach resulted in the findings
consistent with the overall results on COPD exacerbation
rates. In addition, no interaction was observed between
sex and tobacco and biomass smoke both before and after
matching. However, although controversies still arise,
women can be more susceptible of the effects of tobacco
and biomass smoke then men, leading to more severe dis-
ease for the equivalent quantity of smoke [1, 35].
The current study has several limitations, such as its ob-
servational design and the small number of patients with
COPD associated with biomass smoke. There was a possi-
bility of recall bias as the data regarding exposure to bio-
mass and tobacco smoke were collected at the time of or
after the diagnosis of COPD. Although we included partic-
ipants aged 40 years or older, COPD associated with bio-
mass smoke could be prevalent in younger adults [36].
Conclusions
In conclusion, this study shows that patients with COPD
associated with biomass smoke and those with COPD
associated with tobacco smoke have a similar risk of ex-
acerbations. This suggests that any patient with COPD
associated with biomass smoke should be treated ac-
tively. In addition, management strategies should not be
confined to pharmacologic treatment, and should be
complemented by interventions, such as improvement of
kitchen ventilation, introduction of non-polluting cooking
stoves, and use of clean fuels, to reduce exposure to
smoke from biomass fuels.
Additional file
Additional file 1: Online supplement (DOC). Figure S1. Histograms
showing propensity score distribution. Table S1. Baseline characteristics
of the study patients before and after propensity score matching. Table S2.
Adjusted incidence rates of moderate or severe exacerbations by exposure
groups (sensitivity analysis). Table S3. Incidence rates of moderate or severe
exacerbations in the propensity score-matched cohort (sensitivity analysis)
(DOC 117 kb)
Abbreviations
CAT: COPD assessment test; COPD: chronic obstructive pulmonary disease;
KOCOSS: Korean COPD Subgroup Study; KOLD: Korean Obstructive Lung
Disease; mMRC: modified Medical Research Council; SGRQ-C: St. George’s
respiratory questionnaire for COPD
Acknowledgements
We thank all investigators of the KOLD and KOCOSS for its contribution on
patient enrollment and data acquisition. The KOLD was built with the
support of a grant of the Korea Healthcare Technology R&D Project, Ministry
for Health and Welfare, Republic of Korea (A102065).
Funding
None declared.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
CHL. had full access to all of the data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analysis. JC. and CHL.
contributed to the study concept and design, analysis and interpretation of data,
and writing and revision of the manuscript. SSH. contributed to data analysis.
KUK., SHL., HYP., SJP., KHM., YMO., KHY., and KSJ. contributed to patient enrollment
and data acquisition. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The present study was approved by the institutional review board of the
Seoul National University Hospital (H-1706-079-859) and was conducted in
accordance with the tenets of the Declaration of Helsinki. All participants in




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Cho et al. BMC Pulmonary Medicine           (2019) 19:68 Page 8 of 10
Author details
1Division of Pulmonary and Critical Care Medicine, Department of Internal
Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu,
Seoul 03080, Republic of Korea. 2Department of Public Health Science,
Graduate School of Public Health, Seoul National University, Seoul, Republic
of Korea. 3Department of Internal Medicine, Pusan National University School
of Medicine, Busan, Republic of Korea. 4Division of Pulmonary, Critical Care
and Sleep Medicine, Department of Internal Medicine, St. Paul’s Hospital,
College of Medicine, The Catholic University of Korea, Seoul, Republic of
Korea. 5Division of Pulmonary and Critical Care Medicine, Department of
Medicine, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, Republic of Korea. 6Department of Internal Medicine,
Chonbuk National University Medical School, Jeonju, Republic of Korea.
7Division of Pulmonary, Allergy and Critical Care Medicine, Department of
Internal Medicine, Korea University Guro Hospital, Korea University College of
Medicine, Seoul, Republic of Korea. 8Department of Pulmonary and Critical
Care Medicine, Asan Medical Center, University of Ulsan College of Medicine,
Seoul, Republic of Korea. 9Division of Pulmonary and Critical Care Medicine,
Department of Internal Medicine, Konkuk University Medical Center, Konkuk
University School of Medicine, Seoul, Republic of Korea. 10Division of
Pulmonary, Allergy and Critical Care Medicine, Department of Internal
Medicine, Hallym University Sacred Heart Hospital, Hallym University College
of Medicine, Anyang, Republic of Korea.
Received: 12 November 2018 Accepted: 13 March 2019
References
1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et
al. Global strategy for the diagnosis, management, and prevention of
chronic obstructive lung disease 2017 report. GOLD executive summary. Am
J Respir Crit Care Med. 2017;195:557–82.
2. Orozco-Levi M, Garcia-Aymerich J, Villar J, Ramirez-Sarmiento A, Anto JM,
Gea J. Wood smoke exposure and risk of chronic obstructive pulmonary
disease. Eur Respir J. 2006;27:542–6.
3. Kurmi OP, Semple S, Simkhada P, Smith WC, Ayres JG. COPD and chronic
bronchitis risk of indoor air pollution from solid fuel: a systematic review
and meta-analysis. Thorax. 2010;65:221–8.
4. Hu G, Zhou Y, Tian J, Yao W, Li J, Li B, et al. Risk of COPD from exposure to
biomass smoke: a metaanalysis. Chest. 2010;138:20–31.
5. Po JY, FitzGerald JM, Carlsten C. Respiratory disease associated with solid
biomass fuel exposure in rural women and children: systematic review and
meta-analysis. Thorax. 2011;66:232–9.
6. Zhou Y, Zou Y, Li X, Chen S, Zhao Z, He F, et al. Lung function and
incidence of chronic obstructive pulmonary disease after improved cooking
fuels and kitchen ventilation: a 9-year prospective cohort study. PLoS Med.
2014;11:e1001621.
7. World Health Statistics. Monitoring health for the SDGs. World Health
Organization. 2017;2017 http://www.who.int/gho/publications/world_
health_statistics/2017/en/. Accessed Oct 6 2017.
8. World Energy Outlook. International energy agency publications. In: 2017;
2017. https://webstore.iea.org/weo-2017-special-report-energy-access-outlook.
9. Torres-Duque CA, Garcia-Rodriguez MC, Gonzalez-Garcia M. Is chronic
obstructive pulmonary disease caused by wood smoke a different
phenotype or a different entity? Arch Bronconeumol. 2016;52:425–31.
10. Camp PG, Ramirez-Venegas A, Sansores RH, Alva LF, McDougall JE, Sin DD,
et al. COPD phenotypes in biomass smoke- versus tobacco smoke-exposed
Mexican women. Eur Respir J. 2014;43:725–34.
11. Zhao D, Zhou Y, Jiang C, Zhao Z, He F, Ran P. Small airway disease: a
different phenotype of early stage COPD associated with biomass smoke
exposure. Respirology. 2018;23:198–205.
12. Fernandes L, Gulati N, Fernandes Y, Mesquita AM, Sardessai M, Lammers JJ,
et al. Small airway imaging phenotypes in biomass- and tobacco smoke-
exposed patients with COPD. ERJ Open Res. 2017;3.
13. Ramirez-Venegas A, Sansores RH, Perez-Padilla R, Regalado J, Velazquez A,
Sanchez C, et al. Survival of patients with chronic obstructive pulmonary
disease due to biomass smoke and tobacco. Am J Respir Crit Care Med.
2006;173:393–7.
14. Ramirez-Venegas A, Sansores RH, Quintana-Carrillo RH, Velazquez-Uncal M,
Hernandez-Zenteno RJ, Sanchez-Romero C, et al. FEV1 decline in patients
with chronic obstructive pulmonary disease associated with biomass
exposure. Am J Respir Crit Care Med. 2014;190:996–1002.
15. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and
prevention. Lancet. 2007;370:786–96.
16. Park TS, Lee JS, Seo JB, Hong Y, Yoo JW, Kang BJ, et al. Study design and
outcomes of Korean obstructive lung disease (KOLD) cohort study. Tuberc
Respir Dis (Seoul). 2014;76:169–74.
17. Lee JY, Chon GR, Rhee CK, Kim DK, Yoon HK, Lee JH, et al. Characteristics of
patients with chronic obstructive pulmonary disease at the first visit to a
pulmonary medical Center in Korea: the KOrea COpd subgroup study team
cohort. J Korean Med Sci. 2016;31:553–60.
18. Dzioubinski O, Chipman R. Trends in consumption and production:
household energy consumption. DESA discussion paper no. 6. United
Nations Department of Economic and Social Affairs. 1999. https://
sustainabledevelopment.un.org/index.php?page=view&type=400&nr=
77&menu=1572. Accessed Oct 18 2017.
19. Best H, Wolf C. The SAGE handbook of regression analysis and causal
inference. Thousand Oaks, CA: SAGE Publications; 2014.
20. Fletcher C. Standardised questionnaire on respiratory symptoms: a
statement prepared and approved by the MRC Committee on the
Aetiology of chronic bronchitis (MRC breathlessness score). BMJ. 1960;
2:1665.
21. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure
of health status for chronic airflow limitation. The St. George's respiratory
questionnaire. Am Rev Respir Dis. 1992;145:1321–7.
22. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N.
Development and first validation of the COPD assessment test. Eur Respir J.
2009;34:648–54.
23. Yoon HK, Park YB, Rhee CK, Lee JH, Oh YM. Summary of the chronic
obstructive pulmonary disease clinical practice guideline revised in 2014 by
the Korean academy of tuberculosis and respiratory disease. Tuberc Respir
Dis (Seoul). 2017;80:230–40.
24. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.
Salmeterol and fluticasone propionate and survival in chronic obstructive
pulmonary disease. N Engl J Med. 2007;356:775–89.
25. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year
trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med.
2008;359:1543–54.
26. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al.
Indacaterol-Glycopyrronium versus salmeterol-fluticasone for COPD. N Engl
J Med. 2016;374:2222–34.
27. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al.
Fluticasone furoate and vilanterol and survival in chronic obstructive
pulmonary disease with heightened cardiovascular risk (SUMMIT): a
double-blind randomised controlled trial. Lancet. 2016;387:1817–26.
28. Shapiro SD, Ingenito EP. The pathogenesis of chronic obstructive
pulmonary disease: advances in the past 100 years. Am J Respir Cell Mol
Biol. 2005;32:367–72.
29. Silva R, Oyarzun M, Olloquequi J. Pathogenic mechanisms in chronic
obstructive pulmonary disease due to biomass smoke exposure. Arch
Bronconeumol. 2015;51:285–92.
30. Golpe R, Sanjuan Lopez P, Cano Jimenez E, Castro Anon O, Perez de Llano
LA. Distribution of clinical phenotypes in patients with chronic obstructive
pulmonary disease caused by biomass and tobacco smoke. Arch
Bronconeumol. 2014;50:318–24.
31. Olloquequi J, Silva OR. Biomass smoke as a risk factor for chronic
obstructive pulmonary disease: effects on innate immunity. Innate Immun.
2016;22:373–81.
32. Mehra D, Geraghty PM, Hardigan AA, Foronjy R. A comparison of the
inflammatory and proteolytic effects of dung biomass and cigarette smoke
exposure in the lung. PLoS One. 2012;7:e52889.
33. Gonzalez-Garcia M, Torres-Duque CA, Bustos A, Jaramillo C, Maldonado D.
Bronchial hyperresponsiveness in women with chronic obstructive
pulmonary disease related to wood smoke. Int J Chron Obstruct Pulmon
Dis. 2012;7:367–73.
34. Perez-Padilla R, Regalado J, Vedal S, Pare P, Chapela R, Sansores R, et
al. Exposure to biomass smoke and chronic airway disease in Mexican
women. A case-control study. Am J Respir Crit Care Med. 1996;154:
701–6.
35. Foreman MG, Zhang L, Murphy J, Hansel NN, Make B, Hokanson JE, et al.
Early-onset chronic obstructive pulmonary disease is associated with female
Cho et al. BMC Pulmonary Medicine           (2019) 19:68 Page 9 of 10
sex, maternal factors, and African American race in the COPDGene study.
Am J Respir Crit Care Med. 2011;184:414–20.
36. van Gemert F, Kirenga B, Chavannes N, Kamya M, Luzige S, Musinguzi P, et
al. Prevalence of chronic obstructive pulmonary disease and associated risk
factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional
observational study. Lancet Glob Health. 2015;3:e44–51.
Cho et al. BMC Pulmonary Medicine           (2019) 19:68 Page 10 of 10
